Telix Gets Second FDA Rejection For Kidney Cancer Drug
FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities. read more
FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities. read more
Latest Ratings for URBN Date Firm Action From To Mar 2022 Morgan Stanley Maintains Overweight Mar 2022 Barclays Maintains Overweight Mar 2022 JP Morgan Maintains Neutral View More Analyst Ratings for URBN View the Latest Analyst Ratings read more
World Liberty Financial (CRYPTO: WLFI), a DeFi venture linked to President Donald Trump’s family, is set to debut its governance token WLFI. read more